Sono-Tek Corp. 10-Q Summary: Period Ended August 31, 2010
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for Sono-Tek Corporation, a smaller reporting company, for the period ended August 31, 2010. The company develops and sells ultrasonic atomizing nozzles and coating systems for electronics, medical devices, advanced energy, and industrial applications. As of September 20, 2010, there were 14,437,511 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended Aug 31, 2010 | Six Months Ended Aug 31, 2009 |
|---|---|---|
| Net Sales | $4,715,788 | $3,148,612 |
| Gross Profit | $2,233,300 | $1,564,522 |
| Gross Margin | 47.4% | 49.7% |
| Operating Income | $225,471 | ($129,910) |
| Net Income | $220,640 | ($128,881) |
| Diluted EPS | $0.02 | ($0.01) |
| Cash from Operations | $91,743 | $113,202 |
| Cash and Equivalents (End of Period) | $1,803,484 | $1,504,203 |
| Total Debt (Line of Credit + Current Maturities) | $360,178 | N/A |
| Working Capital | $3,395,433 | N/A |
Liquidity: The company maintained a current ratio of 3.5 to 1. It holds a $750,000 revolving line of credit with $350,000 utilized as of August 31, 2010, leaving $400,000 available.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 50% year-over-year for the six-month period, driven by growth in programmable XYZ units and international sales (which now represent approximately 60% of total revenue).
- Profitability Turnaround: The company returned to profitability, reporting net income of $220,640 compared to a net loss of $128,881 in the prior year period.
- Margin Compression: Gross profit margin decreased from 50% to 47% (six months) and 54% to 46% (three months). Management attributes this to a shift in product mix toward lower-margin programmable XYZ units, decreased sales of high-margin stent coaters, and increased service and freight costs.
- Expense Increases: Operating expenses rose due to increased headcount in engineering and sales, higher international commissions, and a reversal of voluntary salary reductions taken by officers in the prior year.
- Balance Sheet: Working capital increased by approximately $320,000, and stockholders' equity increased by $248,000, primarily due to net income.
Outlook, Risks, and Unusual Items
- Subsequent Event: In September 2010, the company repaid the full $350,000 outstanding balance on its line of credit.
- Market Strategy: Management continues to focus on international expansion and diversification into medical devices (stent coating), advanced energy (solar/fuel cells), and WideTrack coating systems.
- Risks: Forward-looking statements are subject to risks including general economic conditions, competition, timely development of new products, and the ability to enforce patents. The company notes that cash balances occasionally exceed FDIC insurance limits.
- Accounting Estimates: Significant judgment is required for stock-based compensation (using Black-Scholes model) and valuation of deferred tax assets.
Investor Verification Checklist
- Verify the sustainability of the 50% revenue growth given the shift toward lower-margin product lines.
- Confirm the status of the $350,000 line of credit repayment noted as a subsequent event.
- Monitor the trend in gross margins to ensure the product mix shift does not erode profitability long-term.
- Review the allowance for doubtful accounts, which increased by $4,000 during the period.
- Assess the impact of increased operating expenses (salaries, travel, commissions) on future operating leverage.